OA
RMD icon

Oxbow Advisors’s ResMed RMD Stock Holding History

Oxbow Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.57M Buy
28,583
+620
+2% +$129K 0.45% 65
2026
Q1 		$6.28M Buy
27,963
+392
+1% +$97.7K 0.53% 51
2025
Q4 		$6.64M Buy
27,571
+50
+0.2% +$12.8K 0.58% 49
2025
Q3 		$7.53M Buy
27,521
+235
+0.9% +$64.2K 0.7% 31
2025
Q2 		$7.04M Buy
27,286
+14,701
+117% +$3.51M 0.77% 28
2025
Q1 		$2.82M Buy
12,585
+245
+2% +$57.2K 0.3% 72
2024
Q4 		$2.82M Buy
12,340
+34
+0.3% +$8.19K 0.33% 67
2024
Q3 		$3M Buy
12,306
+364
+3% +$81.3K 0.3% 65
2024
Q2 		$2.29M Buy
+11,942
New +$2.42M 0.27% 69

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Oxbow Advisors's RMD Position: Q2 2026 in Review

Oxbow Advisors increased its ResMed (RMD) stake by 2.2% in Q2 2026, buying an estimated $129K and bringing the position to 28,583 shares worth $5.57M. The position accounts for 0.45% of the portfolio, ranked #65.

Oxbow Advisors first reported a position in RMD in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.53M in Q3 2025. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Oxbow Advisors held 28,583 shares of ResMed worth $5.57M as of Q2 2026.
  • Oxbow Advisors bought 620 ResMed shares in Q2 2026, an estimated $129K.
  • ResMed made up 0.45% of Oxbow Advisors's portfolio in Q2 2026, its #65 holding.
  • Oxbow Advisors first reported a position in ResMed in Q2 2024 and has held it in 9 quarters since.
  • Oxbow Advisors's ResMed position peaked at $7.53M in Q3 2025.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Oxbow Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.